What Is Claimed Is:

CLAIMS

1. An antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof specifically binds to an E-protein, Domain II (E-DII) epitope of a Yellow Fever (YF) Virus, wherein the antibody or antigen-binding portion thereof comprises the three CDRs of a light chain variable region (VL) comprising the amino acid sequence of SEQ ID. NO: 38 and the three CDRs of a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID. NO: 4.

2. The antibody or antigen-binding portion thereof of claim 1, wherein the antibody or antigen-binding portion thereof comprises a VH and a VL, wherein the VH comprises the amino acid sequence of SEQ ID. NO: 4, the VL comprises the amino acid sequence of SEQ ID. NO: 38.

3. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a human antibody or antigen-binding portion thereof, a monoclonal antibody or antigen-binding portion thereof, a chimeric antibody or antigen-binding portion thereof, or a humanized antibody or antigen-binding portion thereof.

4. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is a single chain antibody or antigen-binding portion thereof, a F(ab') 2 fragment, a dAb fragment, a Fab fragment, or a Fv fragment.

5. The antibody or antigen-binding portion thereof of any of the preceding claims, wherein the antibody or antigen-binding portion thereof is an isolated antibody or antigen-binding portion thereof.

6. A composition comprising an antibody or antigen-binding portion thereof of any of the preceding claims and a carrier.

7. The composition of claim 6, wherein the composition is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier.

8. An antibody or antigen-binding portion thereof for use in medicament, wherein the antibody or antigen-binding portion thereof is any of claims 1-5.

9. Use of the antibody or antigen-binding portion thereof of any of claims 1-5 in the manufacture of a medicament for treating a disease or condition associated with Yellow Fever Virus.

10. A nucleic acid comprising a nucleotide sequence encoding the heavy chain variable region (VH) and light chain variable region (VL) of the antibody or antigen-binding portion thereof of any of claims 1-4.

11. A vector comprising the nucleic acid of claim 10.

12. The vector of claim 11, wherein the vector is an expression vector.

13. A host cell comprising the nucleic acid of claim 10 or the vector of claim 11 or 12.

14. A method for producing an antibody or antigen-binding portion thereof, comprising:

culturing the host cell of claim 13 under conditions allowing for expression of the antibody.

15. The method of claim 14, further comprising harvesting the antibody or antigen-binding portion thereof.

16. The method of claim 14 or 15, wherein the antibody or antigen-binding portion thereof specifically binds to the E-DII epitope of Yellow Fever Virus E-protein.